BioCentury | Aug 4, 2020
Deals

Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate

Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development. TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax $5 million up front...
BC Week In Review | Mar 22, 2019
Financial News

Dynavax commercializing Heplisav-B with $75M debt financing

To fund the commercialization of its Heplisav-B HBV vaccine, Dynavax announced March 18 it was drawing down a $75 million non-dilutive loan through an existing agreement with CRG Servicing LLC. Dynavax Technologies Corp. (NASDAQ:DVAX) drew...
BC Week In Review | May 18, 2018
Clinical News

Dynavax reports updated data for TLR9 agonist combo

Dynavax Technologies Corp. (NASDAQ:DVAX) reported updated response data from the Phase Ib/II MEL-01 (KEYNOTE-184) trial evaluating its SD-101 plus PD-1 inhibitor Keytruda pembrolizumab to treat unresectable stage IIIc or IV melanoma. The data were released...
BC Extra | May 17, 2018
Clinical News

Dynavax falls on updated data for TLR9 agonist combo

Dynavax Technologies Corp. (NASDAQ:DVAX) lost $2.65 (14%) to $16.70 Thursday after reporting updated response data from the Phase Ib/II MEL-01 (KEYNOTE-184) trial evaluating its SD-101 plus PD-1 inhibitor Keytruda pembrolizumab to treat unresectable stage IIIc...
BC Week In Review | Apr 27, 2018
Clinical News

Dynavax reports Phase Ib/II head and neck cancer data for TLR9 agonist combo

Dynavax Technologies Corp. (NASDAQ:DVAX) reported interim data from 18 evaluable patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in the Phase Ib/II MEL-01 (KEYNOTE-184) trial showing that SD-101 plus...
Clinical Results | Apr 20, 2018
Clinical Results

Checkmate's CMP-001 among TLR9 agonist combo data highlighted at AACR

Data from combination treatment with toll-like receptor 9 (TLR9) agonists and PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) were presented at the American Association for Cancer Research meeting in Chicago. Checkmate Pharmaceuticals...
BC Extra | Apr 17, 2018
Clinical News

Checkmate's CMP-001 among TLR9 agonist combo data highlighted at AACR

Data from combination treatment with toll-like receptor 9 agonists and PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) were presented at the American Association for Cancer Research meeting in Chicago on Tuesday. Checkmate...
BC Innovations | Feb 7, 2018
Distillery Therapeutics

Cancer

INDICATION: Lymphoma; breast cancer; colorectal cancer Mouse studies suggest intratumoral injection of a TLR9 agonist and an agonist antibody against OX40 could help treat lymphoma, breast cancer and colorectal cancer. In a mouse model of...
BC Extra | Feb 1, 2018
Preclinical News

Local injection of immunotherapy could be more effective than systemic

In a paper published in Science Translational Medicine , a team from Stanford University led by Ronald Levy showed that an immunotherapy treatment comprising a toll-like receptor 9 (TLR9) agonist and an agonistic antibody against tumor...
BC Week In Review | Sep 15, 2017
Clinical News

Amicus' SD-101 misses in Phase III for skin blistering disorder

Amicus Therapeutics Inc. (NASDAQ:FOLD) reported top-line data showing that SD-101 missed the two primary endpoints in the Phase III ESSENCE trial to treat simplex, recessive dystrophic or junctional non-Herlitz epidermolysis bullosa (EB). Based on the...
Items per page:
1 - 10 of 44